Kristen Kluska
Stock Analyst at Cantor Fitzgerald
(4.40)
# 335
Out of 5,131 analysts
238
Total ratings
43.98%
Success rate
27.35%
Average return
Main Sectors:
Stocks Rated by Kristen Kluska
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EPRX Eupraxia Pharmaceuticals | Maintains: Overweight | $11 → $19 | $8.22 | +131.28% | 2 | Jan 15, 2026 | |
| FOLD Amicus Therapeutics | Downgrades: Neutral | $21 → $15 | $14.32 | +1.29% | 8 | Dec 19, 2025 | |
| DBVT DBV Technologies | Maintains: Overweight | $42 → $48 | $20.35 | +135.87% | 2 | Dec 17, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Overweight | $15 → $24 | $10.35 | +131.88% | 5 | Dec 8, 2025 | |
| LXEO Lexeo Therapeutics | Initiates: Overweight | $19 | $6.10 | +211.48% | 2 | Dec 1, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Overweight | $29 → $24 | $8.57 | +180.05% | 4 | Nov 6, 2025 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $32 → $38 | $34.97 | +8.66% | 9 | Nov 5, 2025 | |
| IRON Disc Medicine | Maintains: Overweight | $132 → $153 | $61.06 | +150.59% | 9 | Oct 17, 2025 | |
| SUPN Supernus Pharmaceuticals | Maintains: Overweight | $46 → $63 | $51.56 | +22.19% | 4 | Sep 30, 2025 | |
| QURE uniQure | Maintains: Overweight | $47 → $80 | $21.76 | +267.65% | 10 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $105 | $20.00 | +425.00% | 20 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $118 | $69.28 | +70.34% | 21 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $74 | $51.85 | +42.72% | 2 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $16 | $5.65 | +183.19% | 1 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $22.45 | +33.63% | 6 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $163 → $81 | $17.52 | +362.33% | 16 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $4.53 | +54.53% | 16 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $67 → $123 | $38.29 | +221.27% | 6 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $3.32 | +2,610.84% | 4 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $0.38 | +1,721.02% | 10 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $16.07 | +55.57% | 9 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $67 | $22.82 | +193.60% | 15 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $3.78 | +349.74% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $3.45 | +131.88% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 | $1.17 | +840.17% | 6 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $18 | $4.97 | +262.54% | 8 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 | $0.71 | +1,872.47% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $1.07 | +1,120.66% | 7 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $1.07 | +1,862.62% | 3 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $1.65 | +264.74% | 3 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $20 | $0.44 | +4,417.73% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $23 | $7.03 | +227.17% | 2 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $900 | $0.82 | +109,123.30% | 1 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $400 | $30.99 | +1,190.74% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,250 → $85 | $2.26 | +3,661.06% | 3 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $6.46 | +2,686.38% | 1 | Dec 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $1.47 | +12,144.90% | 1 | May 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $11 | $1.39 | +691.37% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.42 | +4,125.35% | 2 | Mar 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $0.95 | +9,373.68% | 1 | Dec 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $10,620 → $2,520 | $0.59 | +425,575.68% | 2 | Jan 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $3,040 | $5.41 | +56,092.24% | 1 | Jan 9, 2020 |
Eupraxia Pharmaceuticals
Jan 15, 2026
Maintains: Overweight
Price Target: $11 → $19
Current: $8.22
Upside: +131.28%
Amicus Therapeutics
Dec 19, 2025
Downgrades: Neutral
Price Target: $21 → $15
Current: $14.32
Upside: +1.29%
DBV Technologies
Dec 17, 2025
Maintains: Overweight
Price Target: $42 → $48
Current: $20.35
Upside: +135.87%
Fulcrum Therapeutics
Dec 8, 2025
Maintains: Overweight
Price Target: $15 → $24
Current: $10.35
Upside: +131.88%
Lexeo Therapeutics
Dec 1, 2025
Initiates: Overweight
Price Target: $19
Current: $6.10
Upside: +211.48%
Zevra Therapeutics
Nov 6, 2025
Maintains: Overweight
Price Target: $29 → $24
Current: $8.57
Upside: +180.05%
Rigel Pharmaceuticals
Nov 5, 2025
Maintains: Neutral
Price Target: $32 → $38
Current: $34.97
Upside: +8.66%
Disc Medicine
Oct 17, 2025
Maintains: Overweight
Price Target: $132 → $153
Current: $61.06
Upside: +150.59%
Supernus Pharmaceuticals
Sep 30, 2025
Maintains: Overweight
Price Target: $46 → $63
Current: $51.56
Upside: +22.19%
uniQure
Sep 25, 2025
Maintains: Overweight
Price Target: $47 → $80
Current: $21.76
Upside: +267.65%
Sep 5, 2025
Reiterates: Overweight
Price Target: $105
Current: $20.00
Upside: +425.00%
Sep 3, 2025
Reiterates: Overweight
Price Target: $118
Current: $69.28
Upside: +70.34%
Aug 27, 2025
Reiterates: Overweight
Price Target: $74
Current: $51.85
Upside: +42.72%
May 22, 2025
Assumes: Overweight
Price Target: $16
Current: $5.65
Upside: +183.19%
May 14, 2025
Reiterates: Overweight
Price Target: $30
Current: $22.45
Upside: +33.63%
May 7, 2025
Maintains: Overweight
Price Target: $163 → $81
Current: $17.52
Upside: +362.33%
Apr 28, 2025
Reiterates: Overweight
Price Target: $7
Current: $4.53
Upside: +54.53%
Mar 27, 2025
Maintains: Overweight
Price Target: $67 → $123
Current: $38.29
Upside: +221.27%
Mar 26, 2025
Reiterates: Overweight
Price Target: $90
Current: $3.32
Upside: +2,610.84%
Mar 18, 2025
Reiterates: Overweight
Price Target: $7
Current: $0.38
Upside: +1,721.02%
Mar 4, 2025
Reiterates: Overweight
Price Target: $25
Current: $16.07
Upside: +55.57%
Jan 29, 2025
Reiterates: Overweight
Price Target: $67
Current: $22.82
Upside: +193.60%
Dec 17, 2024
Initiates: Overweight
Price Target: $17
Current: $3.78
Upside: +349.74%
Dec 17, 2024
Initiates: Overweight
Price Target: $8
Current: $3.45
Upside: +131.88%
Nov 22, 2024
Reiterates: Overweight
Price Target: $11
Current: $1.17
Upside: +840.17%
Oct 29, 2024
Reiterates: Overweight
Price Target: $18
Current: $4.97
Upside: +262.54%
Sep 20, 2024
Reiterates: Overweight
Price Target: $14
Current: $0.71
Upside: +1,872.47%
Sep 20, 2024
Reiterates: Overweight
Price Target: $13
Current: $1.07
Upside: +1,120.66%
Apr 30, 2024
Reiterates: Overweight
Price Target: $21
Current: $1.07
Upside: +1,862.62%
Feb 5, 2024
Reiterates: Overweight
Price Target: $6
Current: $1.65
Upside: +264.74%
Aug 30, 2023
Downgrades: Neutral
Price Target: $90 → $20
Current: $0.44
Upside: +4,417.73%
Aug 29, 2023
Reiterates: Overweight
Price Target: $23
Current: $7.03
Upside: +227.17%
Aug 24, 2023
Reiterates: Overweight
Price Target: $900
Current: $0.82
Upside: +109,123.30%
Mar 17, 2023
Initiates: Overweight
Price Target: $400
Current: $30.99
Upside: +1,190.74%
Oct 7, 2022
Downgrades: Neutral
Price Target: $1,250 → $85
Current: $2.26
Upside: +3,661.06%
Dec 29, 2021
Initiates: Overweight
Price Target: $180
Current: $6.46
Upside: +2,686.38%
May 26, 2021
Initiates: Overweight
Price Target: $180
Current: $1.47
Upside: +12,144.90%
May 7, 2021
Downgrades: Neutral
Price Target: $15 → $11
Current: $1.39
Upside: +691.37%
Mar 19, 2021
Initiates: Overweight
Price Target: $60
Current: $1.42
Upside: +4,125.35%
Dec 1, 2020
Initiates: Overweight
Price Target: $90
Current: $0.95
Upside: +9,373.68%
Jan 30, 2020
Assumes: Overweight
Price Target: $10,620 → $2,520
Current: $0.59
Upside: +425,575.68%
Jan 9, 2020
Initiates: Overweight
Price Target: $3,040
Current: $5.41
Upside: +56,092.24%